



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 15, 2023

Jon Congleton  
Chief Executive Officer  
Mineralys Therapeutics, Inc.  
150 N. Radnor Chester Road, Suite F200  
Radnor, PA 19087

**Re: Mineralys Therapeutics, Inc.**  
**Amendment No. 1 to Registration Statement on Form S-1**  
**Exhibit No. 10.9**  
**Filed February 2, 2023**  
**File No. 333-269282**

Dear Jon Congleton:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance